LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has granted Patent No. 10-2665487 titled, "Prevention and Treatment of Inflammatory Conditions." GRI Bio is currently advancing its lead program GRI-0621, a small molecul ...

GRI Bio (NASDAQ:GRI) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. GRI Bio plans to offer up to 2,238,806 shares of GRI stock. Each of these shares comes with one Series C-1 warrant and one Series C-2 warrant. Each of these can be exercised for another share of GRI. GRI Bio doesn't have a firm price ready for its public offering just yet. Instead, it's operating off of an assumed price of $2.68 per share. This is also th ...

GRI's common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 The 1-for-13 Reverse Split will automatically convert every thirteen (13) current shares of the Company's common stock into one (1) share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company's common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal ...

Company Overview - GRI Bio, Inc. is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [3][9] - The company's lead program, GRI-0621, is an oral therapeutic aimed at treating idiopathic pulmonary fibrosis, addressing a significant unmet medical need [9] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [9] Reverse Stock Split Announcement - The board of directors approved a 1-for-13 reverse stock split, reducing the number of outstanding shares from approximately 6,605,271 to about 508,091 shares [3][8] - The reverse split is intended to increase the per share trading price to comply with Nasdaq's minimum bid price requirement [3][6] - The reverse split will take effect on June 17, 2024, and trading under a new CUSIP number will begin on June 18, 2024 [3][6] Stockholder Impact - Stockholders holding shares electronically will not need to take action to receive post-split shares, while those with physical certificates will receive instructions for exchanging them [6][8] - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment based on the adjusted closing sale price [8]

LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 11:00 AM ET. About GRI Bio, Inc. Live video webcast on Tuesday, June 18th at 11:00 AM ET A live video webcast of the presentation wi ...

Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to watch the "What This Means" segment LA JOLLA, CA, May 22, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune disease ...

Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to watch the "What This Means" segment LA JOLLA, CA, May 22, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseas ...

Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024 Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion1 Key Highlights Observed from GRI Preclinical Studies Data presented at the 14th International Congress on Autoimmunity LA JOLLA, CA, May 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advanci ...

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung inflammation Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q3 2024 and topline data in Q4 2024 Data presented at the 2024 American Thoracic Society International Conference LA JOLLA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDA ...

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung inflammation Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q3 2024 and topline data in Q4 2024 Data presented at the 2024 American Thoracic Society International Conference LA JOLLA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDA ...